INAB Insider Trading Activity and SEC Form 4 Filings
INAB insider trading summary
No open-market insider purchases or sales of In8bio, Inc. (INAB) have been reported on SEC Form 4 in the past 12 months.
Latest INAB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 13, 2023 | Jeremy R. Graff | Director | Buy | $2K (2,500 @ $0.95) |
| Aug 25, 2023 | Patrick McCall | Chief Financial Officer | Buy | $1K (1,000 @ $1.03) |
| Aug 24, 2023 | William Tai-Wei Ho | President and CEO | Buy | $25K (23,800 @ $1.05) |
| Dec 12, 2022 | BIOS Fund III NT, LP | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | Aaron G.L. Fletcher | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | BIOS Fund II NT, LP | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | BIOS Fund II, LP | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | BIOS Fund II QP, LP | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | BIOS Incysus Co-Invest I, LP | Director | Buy | $23K (9,214 @ $2.48) |
| Dec 12, 2022 | Bios Equity Partners II, LP | Director | Buy | $23K (9,214 @ $2.48) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.